Comment by liamconnell

The CFO isn't talking about selling tokens to pharma companies. There's no money in that. She proposed revenue sharing. In this scenario, OpenAI's AI service helps discover drug candidates, and shares the IP ownership of the candidate (which is basically a risky bet that it will get through clinical trials and be profitable). Biotech is a complicated market filled with smart people and great negotiators - they dont give away IP ownership without a lot of thought.

If OpenAI wants anything more valuable than selling tokens, they will need to offer something valuable and differentiated. Right now they are not differentiated in the space at all. Look up "OpenAI Biotech" - anything that they've built themselves?

If any company will have a new product that biotech companies will pay top dollar for, its Google. Deepmind has been in biology (proteins) for almost a decade and they it has subsidiaries like Isomorphic Labs that are bringing products to market.